Immunomodulation by chemotherapeutic agents against Leishmaniasis

Area of Science:

• Parasitology
• Immunology
• Drug Discovery

Background:

• Leishmaniasis presents diverse clinical forms, from cutaneous to fatal visceral disease.
• Current Leishmania treatments, like pentavalent antimony, face challenges due to toxicity and increasing drug resistance, particularly in the Indian subcontinent.
• Existing alternatives such as vaccines are not yet effective, and other drugs are often unaffordable in endemic regions.

Purpose of the Study:

• To review host immune signaling pathways as potential therapeutic targets for Leishmania chemotherapy.
• To highlight the urgent need for novel drug targets due to limitations in current Leishmania treatments.

Main Methods:

• Literature review of host immune responses to Leishmania infection.
• Analysis of signaling pathways involved in Leishmania pathogenesis and host defense.

Main Results:

• Identification of specific host immune signaling pathways implicated in Leishmania infection.
• Evaluation of these pathways as viable targets for novel anti-leishmanial drug development.

Conclusions:

• Host immune signaling pathways represent promising targets for developing new Leishmania chemotherapy.
• Targeting these pathways could overcome existing drug resistance and affordability issues, offering new hope for leishmaniasis treatment.